Yawo H
Department of Neurophysiology, Tohoku University School of Medicine, Sendai 980-8575, Japan.
J Neurosci. 1999 Jul 1;19(13):5293-300. doi: 10.1523/JNEUROSCI.19-13-05293.1999.
I have previously reported that norepinephrine (NE) induces a sustained potentiation of transmitter release in the chick ciliary ganglion through a mechanism pharmacologically distinct from any known adrenergic receptors. Here I report that the adrenergic potentiation of transmitter release was enhanced by a phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX) and by zaprinast, an inhibitor of cGMP-selective phosphodiesterase. Exogenous application of the membrane-permeable cGMP, 8-bromo-cGMP (8Br-cGMP), potentiated the quantal transmitter release, and after potentiation, the addition of NE was no longer effective. On the other hand, 8Br-cAMP neither potentiated the transmitter release nor occluded the NE-induced potentiation. The NE-induced potentiation was blocked by neither nitric oxide (NO) synthase inhibitor nor NO scavenger. The quantal transmitter release was not potentiated by NO donors, e.g., sodium nitroprusside. The NE-induced potentiation and its enhancement by IBMX was antagonized by two inhibitors of protein kinase G (PKG), Rp isomer of 8-(4-chlorophenylthio) guanosine-3', 5'-cyclic monophosphorothioate and KT5823. As with NE-induced potentiation, the effects of 8Br-cGMP on both the resting intraterminal [Ca2+] ([Ca2+]i) and the action potential-dependent increment of [Ca2+]i (DeltaCa) in the presynaptic terminal were negligible. The reduction of the paired pulse ratio of EPSC is consistent with the notion that the NE- and cGMP-dependent potentiation of transmitter release was attributable mainly to an increase of the exocytotic fusion probability. These results indicate that NE binds to a novel adrenergic receptor that activates guanylyl cyclase and that accumulation of cGMP activates PKG, which may phosphorylate a target protein involved in the exocytosis of synaptic vesicles.
我之前曾报道,去甲肾上腺素(NE)通过一种药理学上不同于任何已知肾上腺素能受体的机制,在鸡睫状神经节中诱导递质释放的持续增强。在此我报告,磷酸二酯酶抑制剂3 - 异丁基 - 1 - 甲基黄嘌呤(IBMX)和cGMP选择性磷酸二酯酶抑制剂扎普司特可增强递质释放的肾上腺素能增强作用。膜通透性cGMP(8 - 溴 - cGMP,8Br - cGMP)的外源性应用增强了量子化递质释放,增强后再添加NE则不再有效。另一方面,8Br - cAMP既不增强递质释放,也不阻断NE诱导的增强作用。NE诱导的增强作用既不被一氧化氮(NO)合酶抑制剂阻断,也不被NO清除剂阻断。量子化递质释放不被NO供体(如硝普钠)增强。NE诱导的增强作用及其被IBMX增强的作用被两种蛋白激酶G(PKG)抑制剂——8 - (4 - 氯苯硫基)鸟苷 - 3',5' - 环一磷酸硫代酯的Rp异构体和KT5823拮抗。与NE诱导的增强作用一样,8Br - cGMP对突触前终末静息时的胞内钙离子浓度([Ca2 + ]i)和动作电位依赖性[Ca2 + ]i增加(ΔCa)的影响可忽略不计。兴奋性突触后电流(EPSC)配对脉冲比率的降低与以下观点一致,即NE和cGMP依赖性递质释放增强主要归因于胞吐融合概率的增加。这些结果表明,NE与一种新型肾上腺素能受体结合,该受体激活鸟苷酸环化酶,cGMP的积累激活PKG,PKG可能使参与突触小泡胞吐作用的靶蛋白磷酸化。